Severe Asthma: Biologics and Targeted Therapies

Abstract

Severe asthma represents a complex and heterogeneous subset of asthma cases that remain uncontrolled despite high-intensity therapy. Recent advances in biologic and targeted therapies have transformed the therapeutic landscape, offering hope for improved disease control and quality of life in affected individuals. This review synthesizes current evidence on the epidemiology, pathophysiology, risk factors, clinical features, diagnosis, management, and recent advances in biologic treatments, with an emphasis on practical implications and guideline recommendations for clinicians.

Introduction

Asthma is a chronic inflammatory airway disorder with a significant global burden. While most patients achieve control with conventional therapy, approximately 5–10% of patients have severe asthma that remains refractory to high-dose inhaled corticosteroids (ICS) and additional controller medications. Severe asthma is associated with frequent exacerbations, impaired lung function, and increased morbidity. The advent of biologics and targeted therapies marks a paradigm shift in management, necessitating an updated appraisal of clinical strategies for this challenging population.

Epidemiology / Disease Burden

Severe asthma affects an estimated 5–10% of the total asthma population yet accounts for over 50% of asthma-related healthcare costs. Epidemiological studies indicate that severe asthma is more prevalent in adults compared to children and disproportionately affects women and certain ethnic minorities. The disease is associated with increased hospitalization rates, reduced work productivity, and significant impairment in quality of life. Real-world data underscore the need for effective interventions to reduce exacerbations and healthcare utilization in this group.

Pathophysiology

The pathophysiology of severe asthma is multifaceted, involving persistent airway inflammation, airway remodeling, and hyperresponsiveness. A key feature is the heterogeneity of underlying inflammatory pathways. T2-high asthma, characterized by eosinophilic inflammation and elevated biomarkers such as blood eosinophils and fractional exhaled nitric oxide (FeNO), is mediated by cytokines including interleukin (IL)-4, IL-5, and IL-13. In contrast, T2-low asthma involves neutrophilic or paucigranulocytic inflammation, with less defined molecular targets. This mechanistic diversity underpins the rationale for precision medicine approaches using targeted biologics.

Risk Factors

Risk factors for severe asthma include genetic predisposition, atopic comorbidities (e.g., allergic rhinitis, atopic dermatitis), obesity, smoking, occupational exposures, early viral infections, and poor adherence to therapy. Environmental factors such as air pollution and allergen exposure further contribute to disease severity. Comorbidities like gastroesophageal reflux disease (GERD), obstructive sleep apnea, and psychological stress can exacerbate symptoms and complicate management.

Clinical Features

Clinically, severe asthma is characterized by persistent symptoms (e.g., dyspnea, wheezing, cough), frequent exacerbations requiring systemic corticosteroids, and significant limitation in daily activities despite optimal therapy. Objective findings may include reduced forced expiratory volume in one second (FEV1), increased airway hyperresponsiveness, and evidence of airway remodeling on imaging or histopathology. Comorbid conditions and corticosteroid side effects often complicate the clinical picture.

Diagnosis

The diagnosis of severe asthma requires confirmation of asthma, assessment of adherence and inhaler technique, and exclusion of alternative diagnoses. Objective measures include spirometry, bronchial provocation testing, and biomarker assessment (e.g., blood eosinophils, IgE, FeNO). The European Respiratory Society (ERS)/American Thoracic Society (ATS) definition specifies severe asthma as asthma requiring high-dose ICS plus a second controller, or systemic corticosteroids, to prevent it from becoming uncontrolled, or which remains uncontrolled despite this therapy.

Treatment & Management

Management begins with optimization of conventional therapy, including high-dose ICS, long-acting beta2-agonists (LABA), leukotriene receptor antagonists, and long-acting muscarinic antagonists (LAMA). Non-pharmacological interventions include allergen avoidance, smoking cessation, weight reduction, and management of comorbidities. For patients with persistent uncontrolled symptoms, systemic corticosteroids may be necessary, though their long-term use is limited by significant adverse effects.

Recent Advances / Emerging Therapies

Biologic therapies targeting key inflammatory mediators have revolutionized the management of severe asthma. Anti-IgE (omalizumab), anti-IL-5 (mepolizumab, reslizumab, benralizumab), anti-IL-4Rα (dupilumab), and anti-TSLP (tezepelumab) monoclonal antibodies have shown significant reductions in exacerbation rates, oral corticosteroid dependence, and improvements in lung function and quality of life in selected phenotypes. Patient selection, based on biomarkers such as eosinophil count, IgE level, and FeNO, is critical for optimizing therapeutic outcomes. Ongoing research is evaluating novel targets, including IL-33 and other epithelial cytokines, as well as small molecule inhibitors.

Guideline Recommendations

Current guidelines from GINA, ERS/ATS, and NHLBI advocate for a stepwise approach to asthma management, with biologic agents reserved for patients with severe, uncontrolled asthma who meet specific phenotypic and biomarker criteria. Regular monitoring of response and adverse effects is essential. Biologics should be prescribed by clinicians experienced in their use, with consideration of access, cost, and patient preferences. Multidisciplinary care, including specialist referral and patient education, is recommended to optimize outcomes.

Conclusion

Severe asthma presents significant clinical challenges due to its heterogeneity, morbidity, and impact on healthcare resources. The advent of biologics and targeted therapies, guided by precision medicine principles, offers new hope for individualized, effective management. Continued research, multidisciplinary collaboration, and adherence to evidence-based guidelines will be pivotal in improving patient outcomes and advancing care in severe asthma.